Documents
Mind Medicine Australia Overview
Pioneering a new paradigm for mental health treatment in Australia.
Mind Medicine Australia FAQ
Frequently Asked Questions about Mind Medicine Australia and psychedelics.
Position Statement on Compassionate Access, November 2022
Mind Medicine Australia recommends that at this time psilocybin and MDMA should be allowed for treatment-resistant patients – psilocybin for depression and MDMA for PTSD – on a compassionate need basis.
MMA’s views on the approach of the Royal Australian and New Zealand College of Psychiatrists (RANZCP)
MMA’s views on the approach of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) to the off-label psychiatric use of anaesthetic ketamine compared with its approach to the compassionate use of psilocybin and MDMA.
What is Psychedelic-Assisted therapies?
This paper outlines the therapeutic process of psychedelic-assisted therapies and describes the three distinct therapy phases: preparation, the experience and integration.
Legal Medicine Centres
A list of legal medicine centres abroad.
Mental Health Statistics
Some basic numbers relevant to mental illness in Australia
Certificate in Psychedelic-Assisted Therapies™ FAQ
Frequently asked questions about our Certificate in Psychedelic-Assisted Therapies (CPAT)™.
Mind Medicine Australia Fact Sheet
A 2 page infographic outlining key facts and figures about mental health and Mind Medicine Australia.
Mind Medicine Australia Ebook
A compilation of our mission, an overview of the mental illness crisis and frequently asked questions.
International Psilocybin Trials
A list of current international psilocybin trials.
Psychedelic Medical Research
A detailed review of clinical trials registered with a range of organisations around the globe.
List of Drug/Substances and their negative and positive effects
Here's a list outlining the negative and positive effects of each drug subclass.
Interactions with other Medicines
Psilocybin and interactions with other medicines.
Antidepressant & Psychedelic Drug Interaction Chart
This table outlines the time period required to reduce the intake of antidepressants before administering a psychedelic, in order to maximise its effect.
List of Educational Books and Videos
A collection of books and videos to learn all about psychedelics.
Psychedelic Substances Table
An overview of psychedelic substances scheduling in different countries.
Psychedelic Timeline
A timeline showing the use of plant medicines from ~5000 BCE to the present.
Covid-19 Significant Societal and Mental Health Impacts
Mind Medicine Australia has put together a report documenting Covid-19 Significant Societal and Mental Health Impacts. The report includes: Modelling and Future Predictions, Children and Youth, Mental Health, Unemployment, Domestic and Family Violence, Divorce, Alcohol and Tobacco, Financial Insecurity, Eating Disorders, Refugee and Migrant Issues, Social Media, Hospitalisations and Emergency Department, Crime and Cyber Abuse, Racism, Porn Use
Mystical Experiences Questionnaire
.
Relative Drug Harms
A study comparing relative drug harms of various substances.
FMRI scans comparing psilocybin with the placebo for depression
Increased communication between brain networks shown on fMRI scans.
Application of MDMA in PTSD Psychotherapy
Source: Multidisciplinary Association for Psychedelic Studies (MAPS)
Psychedelic Research Methodology Overview
Research methodology overview for psychedelic medicine
Simple Drug Interactions Chart – Professor David Nutt
Simple Drug Interactions Chart – Professor David Nutt
Mind Medicine Australia TGA Rescheduling Submissions
Mind Medicine Australia Submission Guide
Mind Medicine Australia's overview and instruction on how to make your submission to the TGA.
Medicinal Psilocybin Rescheduling Application
Mind Medicine Australia's application to reschedule Psilocybine from Schedule 9 to Schedule 8 of the Poisons Standard 14 July 2020.
Medicinal MDMA Rescheduling Application
Mind Medicine Australia's application to reschedule N, α-DIMETHYL 3,4(METHYLENEDIOXY) PHENYLETHYLAME (MDMA) from Schedule 9 to Schedule 8 of the Poisons Standard 15 July 2020.
Other Documents Relevant to the Rescheduling
RANZCP CM Therapeutic use of Psychedelic Substances - May 2020
The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has developed this memorandum to provide information for psychiatrists about the potential utility of psychedelic therapies for the treatment of certain mental illnesses.
RANZCP CM Therapeutic use of Psychedelic Substances - May 2023
The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has developed this memorandum to provide information for psychiatrists about psychedelic - assisted therapy (PAT) using MDMA to assist in treating PTSD and psilocybin to assist in treating treatment resistant depression (TRD).
Critique of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) psychedelic therapy CM
Critique of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) psychedelic therapy Clinical Memorandum, May 2020
Letter to Dr Nigel Strauss from MMA in response to the RANZCP's Draft Clinical Memorandum circulated in April 2023 on the Therapeutic Use of MDMA and Psilocybin
MMA Response to the Draft Clinical Memorandum (April 2023) on the Therapeutic Use of MDMA for PTSD and Psilocybin for Treatment Resistant Depression.
Mind Medicine Australia Branding
Logos
MMA logo in various formats